Genome-wide studies showed that EZH2 levels are negatively correlated with CD8+ T cells, mainly inhibiting the production of tumor TH1-type chemokines CXCL9 and CXCL10 and thus reducing the recruitment of T cells (22, 26, 27), while the binding of carboxyl structure of ARID1A to EZH2 can reverse this step (28). The gene discussed is CXCL10; the disease is neoplasm.